Drug General Information
Drug ID
D0RV4P
Former ID
DNCL002529
Drug Name
Daratumumab
Drug Type
Antibody
Indication Multiple myeloma [ICD9: 203; ICD10:C90] Approved [524935], [542416]
Company
Genmab Princeton, NJ
Target and Pathway
Target(s) CD38 Target Info [533308]
KEGG Pathway Nicotinate and nicotinamide metabolism
Metabolic pathways
Calcium signaling pathway
Hematopoietic cell lineage
Oxytocin signaling pathway
Salivary secretion
Pancreatic secretion
Epstein-Barr virus infection
NetPath Pathway Leptin Signaling Pathway
TCR Signaling Pathway
PANTHER Pathway CCKR signaling map ST
WikiPathways Oxytocin signaling
References
Ref 524935ClinicalTrials.gov (NCT02252172) Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma. U.S. National Institutes of Health.
Ref 542416(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7395).
Ref 533308Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.